Triera Biosciences Offers New CRO Services Focused on Aptamer Discovery

Triera Biosciences Ltd., a subsidiary of Zentek Ltd., announced the launch of its contract research organization (CRO) services. These services focus on custom aptamer discovery, biosensor enablement, and machine-learning classification to support pharmaceutical, biotechnology, and diagnostics firms. Backed by a 20-year exclusive license from McMaster University, Triera aims to address the diagnostic needs in infectious diseases and oncology across North America and Europe.

Triera's services leverage collaboration with Dr. Yingfu Li's team, offering a platform that integrates three key capabilities. These include aptamer discovery through SELEX, biosensor engineering, and optional machine-learning systems. The company emphasizes client-funded projects while retaining intellectual property ownership, consistent with Zentek's asset-light strategy.

Triera's portfolio includes aptamers targeting significant diseases like influenza A, SARS-CoV-2, and cancer biomarkers such as VEGF. This positions Triera to meet high-priority diagnostic gaps while potentially expanding into new partnerships and licensing agreements.